Transcatheter arterial chemoembolization to reduce size of hepatocellular carcinoma before radiofrequency ablation

Soichiro Ako, Shinichiro Nakamura, Kazuhiro Nouso, Chihiro Dohi, Nozomu Wada, Yuki Morimoto, Yasuto Takeuchi, Tetsuya Yasunaka, Kenji Kuwaki, Hideki Ohnishi, Fusao Ikeda, Hidenori Shiraha, Akinobu Takaki, Hiroyuki Okada

Research output: Contribution to journalArticle

Abstract

Transcatheter arterial chemoembolization (TACE) is often performed before radiofrequency ablation (RFA) for the treatment of early-stage hepatocellular carcinoma (HCC). TACE prior to RFA can expand the ablated area and reduce the tumor size, facilitating complete ablation. However, the factors correlated with size reduction remain uncertain. The aim of this study was to identify the factors associated with size reduction by TACE and develop a formula to predict the reduction rate. A total of 100 HCC patients treated with TACE followed by RFA at least 20 days later were enrolled. The tumor size was measured at the time of TACE and RFA, and correlations between the reduction rate and 13 clinical factors were examined. A formula to predict the reduction rate was built using the factors obtained by the analysis. Reduction in the tumor size was observed in 69 nodules, and the median reduction rate was 16.2%. A multivariate regression analysis revealed that a large tumor size (p<0.01) and a long interval between the therapies (p=0.01) were factors for a high tumor reduction rate, with tumor size more strongly related to the degree of reduction. A size reduction of more than 10% can be expected by waiting 20 days after TACE when the size of the tumor at TACE is over 25 mm in diameter. The tumor size at TACE and the interval between TACE and RFA were closely correlated with HCC size reduction by TACE.

Original languageEnglish
Pages (from-to)47-52
Number of pages6
JournalActa Medica Okayama
Volume72
Issue number1
Publication statusPublished - Jan 1 2018

Fingerprint

Ablation
Hepatocellular Carcinoma
Tumors
Neoplasms
Statistical Factor Analysis
Multivariate Analysis
Regression Analysis
Regression analysis
Therapeutics

Keywords

  • Hepatocellular carcinoma
  • Interval
  • Radiofrequency ablation
  • Size reduction
  • Transcatheter arterial chemoembolization

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Transcatheter arterial chemoembolization to reduce size of hepatocellular carcinoma before radiofrequency ablation. / Ako, Soichiro; Nakamura, Shinichiro; Nouso, Kazuhiro; Dohi, Chihiro; Wada, Nozomu; Morimoto, Yuki; Takeuchi, Yasuto; Yasunaka, Tetsuya; Kuwaki, Kenji; Ohnishi, Hideki; Ikeda, Fusao; Shiraha, Hidenori; Takaki, Akinobu; Okada, Hiroyuki.

In: Acta Medica Okayama, Vol. 72, No. 1, 01.01.2018, p. 47-52.

Research output: Contribution to journalArticle

Ako, S, Nakamura, S, Nouso, K, Dohi, C, Wada, N, Morimoto, Y, Takeuchi, Y, Yasunaka, T, Kuwaki, K, Ohnishi, H, Ikeda, F, Shiraha, H, Takaki, A & Okada, H 2018, 'Transcatheter arterial chemoembolization to reduce size of hepatocellular carcinoma before radiofrequency ablation', Acta Medica Okayama, vol. 72, no. 1, pp. 47-52.
Ako S, Nakamura S, Nouso K, Dohi C, Wada N, Morimoto Y et al. Transcatheter arterial chemoembolization to reduce size of hepatocellular carcinoma before radiofrequency ablation. Acta Medica Okayama. 2018 Jan 1;72(1):47-52.
Ako, Soichiro ; Nakamura, Shinichiro ; Nouso, Kazuhiro ; Dohi, Chihiro ; Wada, Nozomu ; Morimoto, Yuki ; Takeuchi, Yasuto ; Yasunaka, Tetsuya ; Kuwaki, Kenji ; Ohnishi, Hideki ; Ikeda, Fusao ; Shiraha, Hidenori ; Takaki, Akinobu ; Okada, Hiroyuki. / Transcatheter arterial chemoembolization to reduce size of hepatocellular carcinoma before radiofrequency ablation. In: Acta Medica Okayama. 2018 ; Vol. 72, No. 1. pp. 47-52.
@article{a445989474754b49a2deb4bc48dba9c2,
title = "Transcatheter arterial chemoembolization to reduce size of hepatocellular carcinoma before radiofrequency ablation",
abstract = "Transcatheter arterial chemoembolization (TACE) is often performed before radiofrequency ablation (RFA) for the treatment of early-stage hepatocellular carcinoma (HCC). TACE prior to RFA can expand the ablated area and reduce the tumor size, facilitating complete ablation. However, the factors correlated with size reduction remain uncertain. The aim of this study was to identify the factors associated with size reduction by TACE and develop a formula to predict the reduction rate. A total of 100 HCC patients treated with TACE followed by RFA at least 20 days later were enrolled. The tumor size was measured at the time of TACE and RFA, and correlations between the reduction rate and 13 clinical factors were examined. A formula to predict the reduction rate was built using the factors obtained by the analysis. Reduction in the tumor size was observed in 69 nodules, and the median reduction rate was 16.2{\%}. A multivariate regression analysis revealed that a large tumor size (p<0.01) and a long interval between the therapies (p=0.01) were factors for a high tumor reduction rate, with tumor size more strongly related to the degree of reduction. A size reduction of more than 10{\%} can be expected by waiting 20 days after TACE when the size of the tumor at TACE is over 25 mm in diameter. The tumor size at TACE and the interval between TACE and RFA were closely correlated with HCC size reduction by TACE.",
keywords = "Hepatocellular carcinoma, Interval, Radiofrequency ablation, Size reduction, Transcatheter arterial chemoembolization",
author = "Soichiro Ako and Shinichiro Nakamura and Kazuhiro Nouso and Chihiro Dohi and Nozomu Wada and Yuki Morimoto and Yasuto Takeuchi and Tetsuya Yasunaka and Kenji Kuwaki and Hideki Ohnishi and Fusao Ikeda and Hidenori Shiraha and Akinobu Takaki and Hiroyuki Okada",
year = "2018",
month = "1",
day = "1",
language = "English",
volume = "72",
pages = "47--52",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "1",

}

TY - JOUR

T1 - Transcatheter arterial chemoembolization to reduce size of hepatocellular carcinoma before radiofrequency ablation

AU - Ako, Soichiro

AU - Nakamura, Shinichiro

AU - Nouso, Kazuhiro

AU - Dohi, Chihiro

AU - Wada, Nozomu

AU - Morimoto, Yuki

AU - Takeuchi, Yasuto

AU - Yasunaka, Tetsuya

AU - Kuwaki, Kenji

AU - Ohnishi, Hideki

AU - Ikeda, Fusao

AU - Shiraha, Hidenori

AU - Takaki, Akinobu

AU - Okada, Hiroyuki

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Transcatheter arterial chemoembolization (TACE) is often performed before radiofrequency ablation (RFA) for the treatment of early-stage hepatocellular carcinoma (HCC). TACE prior to RFA can expand the ablated area and reduce the tumor size, facilitating complete ablation. However, the factors correlated with size reduction remain uncertain. The aim of this study was to identify the factors associated with size reduction by TACE and develop a formula to predict the reduction rate. A total of 100 HCC patients treated with TACE followed by RFA at least 20 days later were enrolled. The tumor size was measured at the time of TACE and RFA, and correlations between the reduction rate and 13 clinical factors were examined. A formula to predict the reduction rate was built using the factors obtained by the analysis. Reduction in the tumor size was observed in 69 nodules, and the median reduction rate was 16.2%. A multivariate regression analysis revealed that a large tumor size (p<0.01) and a long interval between the therapies (p=0.01) were factors for a high tumor reduction rate, with tumor size more strongly related to the degree of reduction. A size reduction of more than 10% can be expected by waiting 20 days after TACE when the size of the tumor at TACE is over 25 mm in diameter. The tumor size at TACE and the interval between TACE and RFA were closely correlated with HCC size reduction by TACE.

AB - Transcatheter arterial chemoembolization (TACE) is often performed before radiofrequency ablation (RFA) for the treatment of early-stage hepatocellular carcinoma (HCC). TACE prior to RFA can expand the ablated area and reduce the tumor size, facilitating complete ablation. However, the factors correlated with size reduction remain uncertain. The aim of this study was to identify the factors associated with size reduction by TACE and develop a formula to predict the reduction rate. A total of 100 HCC patients treated with TACE followed by RFA at least 20 days later were enrolled. The tumor size was measured at the time of TACE and RFA, and correlations between the reduction rate and 13 clinical factors were examined. A formula to predict the reduction rate was built using the factors obtained by the analysis. Reduction in the tumor size was observed in 69 nodules, and the median reduction rate was 16.2%. A multivariate regression analysis revealed that a large tumor size (p<0.01) and a long interval between the therapies (p=0.01) were factors for a high tumor reduction rate, with tumor size more strongly related to the degree of reduction. A size reduction of more than 10% can be expected by waiting 20 days after TACE when the size of the tumor at TACE is over 25 mm in diameter. The tumor size at TACE and the interval between TACE and RFA were closely correlated with HCC size reduction by TACE.

KW - Hepatocellular carcinoma

KW - Interval

KW - Radiofrequency ablation

KW - Size reduction

KW - Transcatheter arterial chemoembolization

UR - http://www.scopus.com/inward/record.url?scp=85042387255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042387255&partnerID=8YFLogxK

M3 - Article

C2 - 29463938

AN - SCOPUS:85042387255

VL - 72

SP - 47

EP - 52

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 1

ER -